OXvax Ltd. is a spin out company from the University of Oxford focused on the development of an advanced next generation dendritic cell vaccine platform for the treatment of solid tumour cancers.
The Company’s technology is based on intellectual property from the Fairchild laboratory at the Sir William Dunn School of Pathology. The  technology is a next generation Dendritic Cell (DC) immuno-oncology vaccination platform which is superior to previous technologies by harnessing the beneficial properties of a specialised DC subset, described as CD141+XCR1+ DC. These are generated via differentiation from induced pluripotent stem cells (iPSCs) using a bespoke proprietary protocol providing for manufacture of bulk quantities under cGMP.
The OXvax technology lends itself for either a fully autologous or a semi-allogeneic treatment but the Company is initially focused on the development of an off-the-shelf semi-allogeneic vaccine suitable for the treatment of solid tumour cancers.

Get involved with Advanced Therapies Congress


To speak

Jessica Robinson
+44 208 164 3086



To sponsor or exhibit

Ashlea Foster
+44 208 164 3032